Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05425056 · ClinicalTrials.gov registry record · Phase 3
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
A Phase 3 study, sponsored by Vascular Therapies.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT05425056 is a Phase 3 study that has completed, run by Vascular Therapies. The registered enrollment target is 136 participants.
The verdict
NCT05425056, a Phase 3 study, has completed, sponsored by Vascular Therapies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.
Interventions
- DRUG Sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2025-08-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05425056
The ClinicalTrials.gov registry entry for NCT05425056 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vascular Therapies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sirolimus is the first listed.
NCT05425056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05425056 about?
NCT05425056 is a clinical study titled "A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery". The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.
What is the current status of trial NCT05425056?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2022-08-26. Estimated completion is 2025-08-29.
What interventions are being tested in trial NCT05425056?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT05425056?
This trial is sponsored by Vascular Therapies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.